Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11712
Peer-review started: June 20, 2022
First decision: September 5, 2022
Revised: September 13, 2022
Accepted: October 18, 2022
Article in press: October 18, 2022
Published online: November 16, 2022
Processing time: 140 Days and 23.2 Hours
Myeloma (MM) is a plasma cell malignancy. MM treatment includes induction therapy, consolidation therapy, and maintenance therapy.
Consequently, we divided DXM 40mg administered once a day into 20 mg continuously administered over two days, after which we compared the efficacy and toxicity in DXM 40 mg and 20 mg group as maintenance.
Dexamethasone (DXM) combined with lenolidomide for maintenance treatment of multiple myeloma (MM) in standard-risk patients non-eligible for transplantation.
DXM combined with lenolidomide for maintenance treatment into two groups. And comparsion with efficacy and toxicity.
Eefficience as maintenance treatment in standard-risk patients non-eligible for transplantation. However, DXM 40 mg once per day per week exhibited a higher incidence rate in adverse gastroin
Forty mg once per day every week may be safer and lead to a better quality of life.
The data were analyzed by SPSS 24.0 software. Progression-free survival and overall survival were analyzed using Cox proportional hazard models.